Victor Turcanu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Victor Turcanu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Gideon Lack
Department of Women and Children's Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine King's College London London UK
3 shared publications Alick C. Stephens
King's College London, School of Immunology and Microbial Sciences and School of Life Course Sciences, Guy's Hospital, London, UK
2 shared publications- Alexandra F. Santos
Department of Women and Children's Health (Pediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine King's College London London UK
1 shared publication - Alick C. Stephens
Division of Asthma, Allergy and Lung Biology, Department of Pediatric Allergy, St Thomas' Hospital, King's College London, 2nd Floor, Stairwell B, South Wing, Westminster Bridge Road, London, SE1 7EH UK ; MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK
1 shared publication Alina Munteanu
Faculty of Computer Science, University of Iasi, Iasi, Romania
1 shared publicationAsha Sudra
Division of Asthma, Allergy and Lung Biology, King's College London, and Guys' Hospital, London, United Kingdom; MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, and Guys' Hospital, London, United Kingdom
1 shared publication
Latest Publications
- 9 June 2019
- Published by Springer Nature
- Vol. 2020, 143-152
The Use of Dual-Cell-Tracker Dye Staining for the Identification and Characterization of Peanut-Specific T-Cell Subsets
Cell-tracker fluorescent dye labeling is widely used for investigating antigen-specific immune responses in vitro and in vivo. Here we describe a development of this technique—the use of dual-cell-tracker dye staining for the identification and characterization of the responses of different T-cell subsets to peanut proteins in vitro.
- 9 June 2019
- Published by Springer Nature
- Vol. 2020, 143-152
The Use of Dual-Cell-Tracker Dye Staining for the Identification and Characterization of Peanut-Specific T-Cell Subsets
Cell-tracker fluorescent dye labeling is widely used for investigating antigen-specific immune responses in vitro and in vivo. Here we describe a development of this technique—the use of dual-cell-tracker dye staining for the identification and characterization of the responses of different T-cell subsets to peanut proteins in vitro.
- Open Access
- 1 April 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-11
The expression of CD123 can decrease with basophil activation: implications for the gating strategy of the basophil activation test
Basophil activation test (BAT) reproduces IgE-mediated allergic reactions in vitro and has been used as a diagnostic test. Different markers can be used to identify basophils in whole blood and have implications for the outcome of the test. We aimed to assess changes in the expression of CD123 and HLA-DR following basophil activation and to select the best gating strategy for BAT using these markers. BAT was performed in whole blood from 116 children. Peanut extract, anti-IgE, anti-FcεRI or formyl-methionyl-leucyl-phenylalanin (fMLP) was used for stimulation. Surface expression of CD123, HLA-DR, CD63 and CD203c was evaluated by flow cytometry. In some cases, gating on CD123+/HLA-DR− led to the loss-to-analysis of basophils in conditions where basophils were activated. Adding CD203c as an identification marker restored the cell number. Basophils remained HLA-DR-negative with activation. CD123 expression decreased following stimulation with fMLP (n = 116, p < 0.001), anti-IgE (n = 104, p < 0.001) and peanut (n = 42, p < 0.001). The decrease in the mean fluorescence intensity of CD123 correlated with the up-regulation of basophil activation markers, CD63 (rs = −0.31, p < 0.001) and CD203c (rs = −0.35, p < 0.001). BAT to peanut gating basophils on CD203c+/CD123+/HLA-DR− reduced the false-negatives (1 vs. 5 %) and showed a higher diagnostic accuracy compared to using CD123+/HLA-DR− (97 vs. 91 %). CD203c+ appeared as an alternative gating strategy allowing two-colour BAT. Basophils of a subset of patients down-regulate CD123 with activation. The use of CD203c before gating on CD123+/HLA-DR− cells or in isolation ensures the identification of the entire basophil population and accurate assessment of basophil activation, with important diagnostic implications.
- 1 April 2016
- Published by Wiley in Clinical and Translational Allergy
- Vol. 6 (1) , 1-11
Open AccessThe expression of CD123 can decrease with basophil activation: implications for the gating strategy of the basophil activation test
Basophil activation test (BAT) reproduces IgE-mediated allergic reactions in vitro and has been used as a diagnostic test. Different markers can be used to identify basophils in whole blood and have implications for the outcome of the test. We aimed to assess changes in the expression of CD123 and HLA-DR following basophil activation and to select the best gating strategy for BAT using these markers. BAT was performed in whole blood from 116 children. Peanut extract, anti-IgE, anti-FcεRI or formyl-methionyl-leucyl-phenylalanin (fMLP) was used for stimulation. Surface expression of CD123, HLA-DR, CD63 and CD203c was evaluated by flow cytometry. In some cases, gating on CD123+/HLA-DR− led to the loss-to-analysis of basophils in conditions where basophils were activated. Adding CD203c as an identification marker restored the cell number. Basophils remained HLA-DR-negative with activation. CD123 expression decreased following stimulation with fMLP (n = 116, p < 0.001), anti-IgE (n = 104, p < 0.001) and peanut (n = 42, p < 0.001). The decrease in the mean fluorescence intensity of CD123 correlated with the up-regulation of basophil activation markers, CD63 (rs = −0.31, p < 0.001) and CD203c (rs = −0.35, p < 0.001). BAT to peanut gating basophils on CD203c+/CD123+/HLA-DR− reduced the false-negatives (1 vs. 5 %) and showed a higher diagnostic accuracy compared to using CD123+/HLA-DR− (97 vs. 91 %). CD203c+ appeared as an alternative gating strategy allowing two-colour BAT. Basophils of a subset of patients down-regulate CD123 with activation. The use of CD203c before gating on CD123+/HLA-DR− cells or in isolation ensures the identification of the entire basophil population and accurate assessment of basophil activation, with important diagnostic implications.
- 16 February 2016
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 1 (2) , 169-180
Precise treatment of cystic fibrosis – current treatments and perspectives for using CRISPR
Cystic fibrosis (CF) affects about 70,000 individuals worldwide, whose lives are shortened mainly due to chronic pulmonary infections resulting from impaired clearance of abnormally viscous airway mucus. The development of novel drugs targeting specific CFTR gene mutations in a precision medicine framework improved treatment, so that for patients born in 2000–2003 in the UK, the median life expectancy was estimated at around 40 years. Moreover the discovery of the CRISPR (Classes of Regularly Interspaced Palindromic Repeats) and Cas9 (Crispr-ASsociated) nuclease system opened the perspective of specifically correcting the defective CFTR gene as recently demonstrated in a model of intestinal stem cell organoids from CF patients. In the present review, we shall outline the existing state-of-art treatments and the perspectives for the precision treatment of CF opened by CRISPR.
- 16 February 2016
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 1 (2) , 169-180
Precise treatment of cystic fibrosis – current treatments and perspectives for using CRISPR
Cystic fibrosis (CF) affects about 70,000 individuals worldwide, whose lives are shortened mainly due to chronic pulmonary infections resulting from impaired clearance of abnormally viscous airway mucus. The development of novel drugs targeting specific CFTR gene mutations in a precision medicine framework improved treatment, so that for patients born in 2000–2003 in the UK, the median life expectancy was estimated at around 40 years. Moreover the discovery of the CRISPR (Classes of Regularly Interspaced Palindromic Repeats) and Cas9 (Crispr-ASsociated) nuclease system opened the perspective of specifically correcting the defective CFTR gene as recently demonstrated in a model of intestinal stem cell organoids from CF patients. In the present review, we shall outline the existing state-of-art treatments and the perspectives for the precision treatment of CF opened by CRISPR.
- Open Access
- 1 December 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (6) , 1329-1338.e10
IL-9 is a key component of memory TH cell peanut-specific responses from children with peanut allergy
- 1 December 2014
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 134 (6) , 1329-1338.e10
Open AccessIL-9 is a key component of memory TH cell peanut-specific responses from children with peanut allergy
- 1 October 2012
- Published by Springer Nature in Pediatric Drugs
- Vol. 14 (5) , 317-330
Role of Leukotriene Receptor Antagonists in the Management of Pediatric Asthma
At present, the main indications for leukotriene receptor antagonists (LTRA) in pediatric asthma are as add-on therapy to inhaled corticosteroids (ICS) and as initial controller therapy in children with mild asthma, especially those who cannot or will not use ICS. LTRA are also useful for patients who have concomitant rhinitis, and patients with viral-induced wheeze and exercise-induced asthma. It should be noted that the benefits of LTRA therapy have been demonstrated in children as young as 6 months of age and recent clinical trials have further proven the benefits of LTRA in acute asthma exacerbations. However, considering the important pro-inflammatory effects that leukotrienes (LT) have in experimental models of asthma, it may seem surprising that LTRA treatment outcomes are not better and that in some clinical trials only a minority of patients could be classified as full responders. This could be explained by potential additional LT receptors that are not affected by LTRA. Such receptors could represent new therapeutic targets in asthma. Furthermore, progress in differentiating between asthma phenotypes that result from different pathogenic mechanisms, some of which may involve LT to a lesser degree, should lead to an improved, personalized use of LTRA for treating asthma.
- 1 October 2012
- Published by Springer Nature in Pediatric Drugs
- Vol. 14 (5) , 317-330
Role of Leukotriene Receptor Antagonists in the Management of Pediatric Asthma
At present, the main indications for leukotriene receptor antagonists (LTRA) in pediatric asthma are as add-on therapy to inhaled corticosteroids (ICS) and as initial controller therapy in children with mild asthma, especially those who cannot or will not use ICS. LTRA are also useful for patients who have concomitant rhinitis, and patients with viral-induced wheeze and exercise-induced asthma. It should be noted that the benefits of LTRA therapy have been demonstrated in children as young as 6 months of age and recent clinical trials have further proven the benefits of LTRA in acute asthma exacerbations. However, considering the important pro-inflammatory effects that leukotrienes (LT) have in experimental models of asthma, it may seem surprising that LTRA treatment outcomes are not better and that in some clinical trials only a minority of patients could be classified as full responders. This could be explained by potential additional LT receptors that are not affected by LTRA. Such receptors could represent new therapeutic targets in asthma. Furthermore, progress in differentiating between asthma phenotypes that result from different pathogenic mechanisms, some of which may involve LT to a lesser degree, should lead to an improved, personalized use of LTRA for treating asthma.
- 11 August 2010
- Vol. 59 (2) , 77-82
[Peanut allergy].
Peanut allergy currently affects around 1% of the UK and US paediatric population and represents a major healthcare concern because it is outgrown in less than 20% of cases and is a major cause of anaphylaxis. Its main symptoms, triggered by peanut ingestion, are cutaneous (urticaria, erythema, angioedema), gastrointestinal (abdominal pain, vomiting, diarrhoea), respiratory (wheezing, dyspnoea) and cardiovascular (hypotension, arrhythmia, shock). The usual onset of symptoms occurs soon after peanut ingestion (minutes to hours); however some patients have biphasic reactions, with exacerbations occurring up to 8 hours later. Peanut allergy diagnostic is based mainly upon the medical history (preferably including a diet diary and elimination diets), skin testing, peanut-specific IgE measurement and ideally a peanut oral challenge. Peanut allergy management includes monitorisation and education for avoiding peanut-containing foods and for recognising and treating anaphylactic episodes (self-injectable adrenalin and rapid-acting antihistamines). In the past, anti-IgE antibodies were shown to decrease the risk of anaphylaxis by reducing the allergic patients' reactivity to peanuts. Recent investigations, driven by the need to develop efficient treatment and prevention strategies for peanut allergy, suggest that oral immunotherapy with peanuts, although exposing the patients to significant risk, may represent a promising therapeutic approach. Furthermore, contrary to the general view that peanut avoidance in infants could prevent peanut allergy, a recent study shows that the opposite may be true as early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy.
- 11 August 2010
- Vol. 59 (2) , 77-82
[Peanut allergy].
Peanut allergy currently affects around 1% of the UK and US paediatric population and represents a major healthcare concern because it is outgrown in less than 20% of cases and is a major cause of anaphylaxis. Its main symptoms, triggered by peanut ingestion, are cutaneous (urticaria, erythema, angioedema), gastrointestinal (abdominal pain, vomiting, diarrhoea), respiratory (wheezing, dyspnoea) and cardiovascular (hypotension, arrhythmia, shock). The usual onset of symptoms occurs soon after peanut ingestion (minutes to hours); however some patients have biphasic reactions, with exacerbations occurring up to 8 hours later. Peanut allergy diagnostic is based mainly upon the medical history (preferably including a diet diary and elimination diets), skin testing, peanut-specific IgE measurement and ideally a peanut oral challenge. Peanut allergy management includes monitorisation and education for avoiding peanut-containing foods and for recognising and treating anaphylactic episodes (self-injectable adrenalin and rapid-acting antihistamines). In the past, anti-IgE antibodies were shown to decrease the risk of anaphylaxis by reducing the allergic patients' reactivity to peanuts. Recent investigations, driven by the need to develop efficient treatment and prevention strategies for peanut allergy, suggest that oral immunotherapy with peanuts, although exposing the patients to significant risk, may represent a promising therapeutic approach. Furthermore, contrary to the general view that peanut avoidance in infants could prevent peanut allergy, a recent study shows that the opposite may be true as early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy.
- 11 March 2010
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 40 (4) , 531-533
Could T cell component‐resolved diagnosis differentiate between food sensitization and food allergy?
Cite this as: V. Turcanu, Clinical & Experimental Allergy, 2010 (40) 531–533 .
- 11 March 2010
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 40 (4) , 531-533
Could T cell component‐resolved diagnosis differentiate between food sensitization and food allergy?
Cite this as: V. Turcanu, Clinical & Experimental Allergy, 2010 (40) 531–533 .